PHLDA3

Summary

PHLDA3 (pleckstrin homology like domain family A member 3, HGNC:8934) is a protein-coding gene on chromosome 1q32.1, encoding Pleckstrin homology-like domain family A member 3 (Q9Y5J5). p53/TP53-regulated repressor of Akt/AKT1 signaling.

Enables phosphatidylinositol phosphate binding activity and phosphatidylinositol-3,4-bisphosphate binding activity. Involved in intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; and positive regulation of apoptotic process. Located in plasma membrane.

Source: NCBI Gene 23612 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 15 total
• MANE Select transcript: NM_012396

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8934
Approved symbol	PHLDA3
Name	pleckstrin homology like domain family A member 3
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	TIH1
Ensembl gene	ENSG00000174307
Ensembl biotype	protein_coding
OMIM	607054
Entrez	23612

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000367309, ENST00000367311, ENST00000485436, ENST00000497057

RefSeq mRNA: 1 — MANE Select: NM_012396 NM_012396

CCDS: CCDS1412

Canonical transcript exons

ENST00000367311 — 2 exons

Exon	Start	End
ENSE00001444157	201464278	201466178
ENSE00001444159	201468341	201469188

Expression profiles

Bgee: expression breadth ubiquitous, 222 present calls, max score 98.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.8154 / max 410.9787, expressed in 1597 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16659	17.7887	1573
16658	6.7143	1407
16660	1.8574	858
16654	0.4943	306
16657	0.3467	190
16653	0.2420	100
16656	0.2046	91
16655	0.0935	40
201872	0.0740	25

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibial nerve	UBERON:0001323	98.79	gold quality
lower esophagus mucosa	UBERON:0035834	97.71	gold quality
sural nerve	UBERON:0015488	97.01	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.96	gold quality
lower esophagus	UBERON:0013473	96.57	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.56	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.48	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.26	gold quality
stromal cell of endometrium	CL:0002255	95.64	gold quality
omental fat pad	UBERON:0010414	95.57	gold quality
esophagus	UBERON:0001043	95.55	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.53	gold quality
peritoneum	UBERON:0002358	95.53	gold quality
left coronary artery	UBERON:0001626	95.33	gold quality
descending thoracic aorta	UBERON:0002345	95.33	gold quality
ascending aorta	UBERON:0001496	95.29	gold quality
adipose tissue of abdominal region	UBERON:0007808	95.28	gold quality
thoracic aorta	UBERON:0001515	95.26	gold quality
spinal cord	UBERON:0002240	95.22	gold quality
right coronary artery	UBERON:0001625	95.20	gold quality
esophagus mucosa	UBERON:0002469	95.14	gold quality
skin of leg	UBERON:0001511	95.01	gold quality
coronary artery	UBERON:0001621	94.99	gold quality
apex of heart	UBERON:0002098	94.85	gold quality
right uterine tube	UBERON:0001302	94.84	gold quality
aorta	UBERON:0000947	94.76	gold quality
endocervix	UBERON:0000458	94.64	gold quality
adipose tissue	UBERON:0001013	94.55	gold quality
skin of abdomen	UBERON:0001416	94.54	gold quality
popliteal artery	UBERON:0002250	94.52	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

78 targeting PHLDA3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-1915-3P	99.58	66.79	1988

Literature-anchored findings (GeneRIF, showing 11)

• Study identifies PHLDA3 as a p53 target gene that encodes a PH domain-only protein and finds that PHLDA3 competes with the PH domain of Akt for binding of membrane lipids, inhibiting Akt translocation to the cellular membrane and activation. (PMID:19203586)
• findings indicate somatic mutation of PHLDA3 is rare in common cancer types; PHLDA3 expression was lost in 22% of prostate cancers; these results indicate that PHLDA3 are altered in prostate cancers by loss of expression (PMID:21753719)
• Results indicate that tumor suppressor PHLDA3-mediated pathway is important in the development of pancreatic neuroendocrine tumors (PanNETs). (PMID:24912192)
• Low PHLDA3 expression in ESCC may be predictive of tumor recurrence suggesting that Akt activation may be a therapeutic target in ESCCs (PMID:25667479)
• although iPSCs and ESCs share lots of common features, we did not find that PHLDA3 is important to ES cell differentiation. (PMID:28588267)
• Recommendation of long-term and systemic management according to the risk factors in rectal NETs patients. (PMID:30787304)
• Novel Role for Pleckstrin Homology-Like Domain Family A, Member 3 in the Regulation of Pathological Cardiac Hypertrophy. (PMID:31426686)
• Phlda3 regulates beta cell survival during stress. (PMID:31492921)
• Prognostic and predictive value of Pleckstrin homology-like domain, family A family members in breast cancer. (PMID:33179538)
• PHLDA3 exerts an antitumor function in prostate cancer by down-regulating Wnt/beta-catenin pathway via inhibition of Akt. (PMID:34303965)
• PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis. (PMID:34592332)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	phlda3	ENSDARG00000037804
mus_musculus	Phlda3	ENSMUSG00000041801
rattus_norvegicus	Phlda3	ENSRNOG00000009068

Paralogs (2): PHLDA1 (ENSG00000139289), PHLDA2 (ENSG00000181649)

Protein

Protein identifiers

Pleckstrin homology-like domain family A member 3 — Q9Y5J5 (reviewed: Q9Y5J5)

Alternative names: TDAG51/Ipl homolog 1

All UniProt accessions (1): Q9Y5J5

UniProt curated annotations — full annotation on UniProt →

Function. p53/TP53-regulated repressor of Akt/AKT1 signaling. Represses AKT1 by preventing AKT1-binding to membrane lipids, thereby inhibiting AKT1 translocation to the cellular membrane and activation. Contributes to p53/TP53-dependent apoptosis by repressing AKT1 activity. Its direct transcription regulation by p53/TP53 may explain how p53/TP53 can negatively regulate AKT1. May act as a tumor suppressor.

Subcellular location. Cytoplasm. Membrane.

Tissue specificity. Widely expressed with lowest expression in liver and spleen.

Domain organisation. The PH domain binds phosphoinositides with a broad specificity. It competes with the PH domain of AKT1 and directly interferes with AKT1 binding to phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3), preventing AKT1 association to membrane lipids and subsequent activation of AKT1 signaling.

Induction. By p53/TP53; expression is directly activated by TP53. TP53 phosphorylation on ‘Ser-15’ is required to activate the PHLDA3 promoter.

Miscellaneous. PHLDA3 genomic locus is frequently observed in primary lung cancers, suggesting a role in tumor suppression.

Similarity. Belongs to the PHLDA3 family.

RefSeq proteins (1): NP_036528* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR042832	PHLA1/2/3	Family

Pfam: PF00169

UniProt features (5 total): sequence conflict 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5J5-F1	90.81	0.81

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 173 (showing top): GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE_BY_P53_CLASS_MEDIATOR, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, SP1_Q2_01, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, RICKMAN_METASTASIS_DN, CATTTCA_MIR203, GOBP_APOPTOTIC_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_PHOSPHATIDYLINOSITOL_3_KINASE_PROTEIN_KINASE_B_SIGNAL_TRANSDUCTION, BLALOCK_ALZHEIMERS_DISEASE_UP, GROSS_HYPOXIA_VIA_ELK3_UP, GOBP_PHOSPHATIDYLINOSITOL_3_KINASE_PROTEIN_KINASE_B_SIGNAL_TRANSDUCTION, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP

GO Biological Process (5): anatomical structure morphogenesis (GO:0009653), intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771), positive regulation of apoptotic process (GO:0043065), negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051898), apoptotic process (GO:0006915)

GO Molecular Function (7): phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), phosphatidylinositol-3,4,5-trisphosphate binding (GO:0005547), phosphatidylinositol-5-phosphate binding (GO:0010314), phosphatidylinositol-3-phosphate binding (GO:0032266), phosphatidylinositol-3,4-bisphosphate binding (GO:0043325), phosphatidylinositol-3,5-bisphosphate binding (GO:0080025), phosphatidylinositol phosphate binding (GO:1901981)

GO Cellular Component (3): cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphatidylinositol phosphate binding	5
phosphatidylinositol bisphosphate binding	3
anion binding	2
cellular anatomical structure	2
developmental process	1
anatomical structure development	1
intrinsic apoptotic signaling pathway in response to DNA damage	1
intrinsic apoptotic signaling pathway by p53 class mediator	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
negative regulation of intracellular signal transduction	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
phospholipid binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

497 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PHLDA3	AEN	Q8WTP8	688
PHLDA3	PLEK2	Q9NYT0	603
PHLDA3	PLEK	P08567	599
PHLDA3	KANK3	Q6NY19	537
PHLDA3	CCNG1	P51959	523
PHLDA3	ZMAT3	Q9HA38	521
PHLDA3	CDKN1A	P38936	510
PHLDA3	TP53	P04637	477
PHLDA3	BBC3	Q96PG8	441
PHLDA3	EDA2R	Q9HAV5	435
PHLDA3	MDM2	Q00987	423
PHLDA3	FDXR	P22570	421
PHLDA3	DDIAS	Q8IXT1	405
PHLDA3	BTG2	P78543	397
PHLDA3	PMAIP1	Q13794	391
PHLDA3	INKA2	Q9NTI7	391

IntAct

102 interactions, top by confidence:

A	B	Type	Score
CDK2	PHLDA3	psi-mi:“MI:0915”(physical association)	0.370
	HLA-C	psi-mi:“MI:0914”(association)	0.350
PHLDA3	HSPA8	psi-mi:“MI:0914”(association)	0.350
DNAJC25	TUBAL3	psi-mi:“MI:0914”(association)	0.350
PHLDA3	LRPPRC	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	XPO5	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	ATXN10	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	IPO11	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	ARMC6	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	GCLM	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	PHLDA3	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	DYNLL1	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	UFL1	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	IPO4	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	MAPRE2	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	LBR	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	MYO1A	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	PRPF6	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	SF3B6	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	NUBP2	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	IMMT	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	XPO4	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	TFB2M	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	RARS2	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	ARL1	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	PDXDC1	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	SAAL1	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3		psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	DYNC1H1	psi-mi:“MI:0915”(physical association)	0.000
PHLDA3	COPG2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (29): DNAAF5 (Affinity Capture-MS), NUP93 (Affinity Capture-MS), PDCD6IP (Affinity Capture-MS), TTC27 (Affinity Capture-MS), NUP205 (Affinity Capture-MS), HNRNPM (Affinity Capture-MS), IPO4 (Affinity Capture-MS), SLC25A12 (Affinity Capture-MS), PDXDC1 (Affinity Capture-MS), LRPPRC (Affinity Capture-MS), ATP5L (Affinity Capture-MS), SSR4 (Affinity Capture-MS), TNPO3 (Affinity Capture-MS), MMS19 (Affinity Capture-MS), XPO5 (Affinity Capture-MS)

ESM2 similar proteins: A1L2W9, B2RQE8, B5XG43, G9CGD6, O08969, O88387, P59113, Q0V987, Q0VC85, Q1KKW7, Q1KKZ1, Q32LP0, Q3UUV5, Q3ZBA3, Q4V7G1, Q503L1, Q53GA4, Q5FVW6, Q5PQT7, Q5R8M5, Q5U597, Q5XGP7, Q5ZL23, Q6P0G8, Q6PG29, Q7Z628, Q7Z6J4, Q80VL0, Q80YS6, Q86UX7, Q86WV1, Q8AW35, Q8BY35, Q8IZC4, Q8K1B8, Q8N556, Q8VH46, Q91ZM9, Q91ZT5, Q925E0

Diamond homologs: A1L2W9, B5XG43, O08969, Q0V987, Q0VC85, Q503L1, Q53GA4, Q5PQT7, Q62392, Q8AW35, Q8WV24, Q9QZA1, Q9WV95, Q9Y5J5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 98 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Translation	8	6.9×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

15 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	13
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

248 predictions. Top by Δscore:

Variant	Effect	Δscore
1:201468336:CTTA:C	donor_loss	1.0000
1:201468337:TTA:T	donor_loss	1.0000
1:201468338:TA:T	donor_loss	1.0000
1:201468339:A:AC	donor_gain	0.9900
1:201468340:C:CC	donor_gain	0.9900
1:201468340:CCTG:C	donor_gain	0.9900
1:201468477:TG:T	donor_gain	0.9900
1:201466174:CGAAG:C	acceptor_gain	0.9800
1:201468347:TG:T	donor_gain	0.9800
1:201466177:AGC:A	acceptor_loss	0.9700
1:201466178:GCT:G	acceptor_loss	0.9700
1:201466179:C:CC	acceptor_gain	0.9700
1:201466180:T:G	acceptor_loss	0.9700
1:201468339:ACCTG:A	donor_gain	0.9600
1:201468340:CCTGC:C	donor_gain	0.9600
1:201468343:G:A	donor_gain	0.9600
1:201466177:AG:A	acceptor_gain	0.9400
1:201468346:TTG:T	donor_gain	0.9400
1:201466175:GAAG:G	acceptor_gain	0.9300
1:201468339:AC:A	donor_gain	0.9300
1:201468340:CC:C	donor_gain	0.9300
1:201466176:AAG:A	acceptor_gain	0.9200
1:201468340:CCT:C	donor_gain	0.9100
1:201469120:C:A	donor_gain	0.9100
1:201468341:C:T	donor_gain	0.9000
1:201468348:G:T	donor_gain	0.8700
1:201466181:G:C	acceptor_loss	0.8400
1:201468335:GCT:G	donor_gain	0.7900
1:201468518:T:TA	donor_gain	0.7800
1:201466176:AAGCT:A	acceptor_gain	0.7700

AlphaMissense

807 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:201468533:A:G	F85S	1.000
1:201468505:C:A	W94C	0.999
1:201468505:C:G	W94C	0.999
1:201468507:A:G	W94R	0.999
1:201468507:A:T	W94R	0.999
1:201468568:G:C	F73L	0.999
1:201468568:G:T	F73L	0.999
1:201468569:A:G	F73S	0.999
1:201468570:A:G	F73L	0.999
1:201468709:C:A	W26C	0.999
1:201468709:C:G	W26C	0.999
1:201468711:A:G	W26R	0.999
1:201468711:A:T	W26R	0.999
1:201468494:A:C	I98S	0.998
1:201468494:A:G	I98T	0.998
1:201468506:C:G	W94S	0.998
1:201468710:C:G	W26S	0.998
1:201468736:C:A	K17N	0.998
1:201468736:C:G	K17N	0.998
1:201468531:G:T	R86S	0.997
1:201468532:G:C	F85L	0.997
1:201468532:G:T	F85L	0.997
1:201468534:A:G	F85L	0.997
1:201468623:A:G	F55S	0.997
1:201468689:A:T	L33H	0.997
1:201468700:C:A	K29N	0.997
1:201468700:C:G	K29N	0.997
1:201468735:G:T	R18S	0.997
1:201468472:G:C	F105L	0.996
1:201468472:G:T	F105L	0.996

dbSNP variants (sampled 300 via entrez): RS1000190306 (1:201469285 C>G,T), RS1000342724 (1:201464266 T>C), RS1000774888 (1:201470842 C>G), RS1000776142 (1:201464535 G>A,C), RS1000904953 (1:201468166 A>G), RS1001171190 (1:201464080 C>T), RS1001240486 (1:201463875 G>A), RS1001841233 (1:201468776 G>A), RS1002075818 (1:201468088 C>T), RS1002150062 (1:201469065 A>C), RS1002247817 (1:201464972 C>T), RS1002445787 (1:201469462 C>CATCT), RS1003570999 (1:201467417 C>A,T), RS1003674995 (1:201466747 C>A,T), RS1004003582 (1:201469793 G>T)

Disease associations

OMIM: gene MIM:607054 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004988_443	Breast cancer	4.000000e-13

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	5
Aflatoxin B1	affects expression, increases expression	4
Cisplatin	increases expression	3
Cyclosporine	increases expression	3
sodium arsenite	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
tungsten carbide	affects cotreatment, increases expression	1
chloroacetaldehyde	increases expression	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
deoxynivalenol	increases expression	1
beta-lapachone	increases expression	1
cobaltous chloride	increases expression	1
zinc chromate	increases abundance, increases expression	1
ferrous chloride	decreases expression	1
cupric chloride	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
polyhexamethyleneguanidine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases expression, increases abundance	1
adefovir dipivoxil	increases expression	1
pinostrobin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
MT19c compound	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2AM	Abcam HeLa PHLDA3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.